| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,200 | ₹13.6 0% | 3000% |
| 00% | ₹1,017 0% | 4,300 | ₹1.4 40% | 3,800-5% |
| - | - | 4,400 | ₹1.45 0% | 3,6000% |
| - | - | 4,450 | ₹17.45 0% | 00% |
| 00% | ₹502 0% | 4,500 | ₹2 -9.09% | 3,500-2.77% |
| - | - | 4,550 | ₹3.6 0% | 1,4000% |
| 3000% | ₹500.15 0% | 4,600 | ₹1.85 0% | 5,2000% |
| - | - | 4,650 | ₹5.2 0% | 1,5000% |
| 1,3000% | ₹248.05 0% | 4,700 | ₹2.5 0% | 5,3000% |
| 2,1000% | ₹278.9 0% | 4,750 | ₹4 -33.33% | 4,3000% |
| 1,6000% | ₹430 0% | 4,800 | ₹5.85 -13.97% | 8,5000% |
| 1,9000% | ₹494.95 26.47% | 4,850 | ₹6.75 -15.62% | 4,6000% |
| 7,4000% | ₹468.3 0% | 4,900 | ₹9 -29.68% | 7,700-14.44% |
| 3,000-6.25% | ₹366.35 -9.07% | 4,950 | ₹14.55 5.05% | 10,900-1.80% |
| 19,80012.5% | ₹303.45 -15.97% | 5,000 | ₹17.45 -12.96% | 28,800-4.31% |
| 3,5009.37% | ₹261.35 -18.22% | 5,050 | ₹29 32.42% | 6,9001.47% |
| 9,700-3% | ₹223.15 -20.58% | 5,100 | ₹35.9 -3.62% | 10,700-24.11% |
| 5,6005.66% | ₹184.3 -22.53% | 5,150 | ₹51.7 7.48% | 9,300-10.57% |
| 18,00016.88% | ₹153.8 -24.7% | 5,200 | ₹65.85 4.94% | 22,900-12.59% |
| 10,3006.18% | ₹124.9 -27.21% | 5,250 | ₹86.85 5.91% | 8,90036.92% |
| 38,600-27.57% | ₹100.55 -30.31% | 5,300 | ₹112 10.34% | 29,40088.46% |
| 25,60064.10% | ₹80.5 -31.69% | 5,350 | ₹140.25 11.75% | 8,10084.09% |
| 43,200-8.66% | ₹61.65 -35.71% | 5,400 | ₹175.65 15.1% | 11,9006.25% |
| 7,20030.90% | ₹48.35 -35.4% | 5,450 | ₹207.15 13.22% | 1,600-30.43% |
| 44,900-1.31% | ₹35.6 -41.49% | 5,500 | ₹250.45 15.12% | 7,100-6.57% |
| 2,400-14.28% | ₹23.05 -51% | 5,550 | - | - |
| 36,00031.38% | ₹22.4 -37.95% | 5,600 | ₹309.95 7.21% | 1,50066.66% |
| 2,6000% | ₹10.65 -62.82% | 5,650 | - | - |
| 7,30010.60% | ₹11.1 -48.37% | 5,700 | - | - |
| 3,200-3.03% | ₹7.85 -53.41% | 5,750 | ₹412.35 -0.79% | 600500% |
| 9,80040% | ₹4 -67.07% | 5,800 | - | - |
| 5,300-1.85% | ₹2.5 -61.83% | 5,900 | - | - |
| - | - | 6,000 | ₹740 0% | 1000% |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
